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As treatment options for patients with incurable metastatic castration-resis-
tant prostate cancer (mCRPC) are considerably limited, novel effective
therapeutic options are needed. Checkpoint kinase 1 (CHK1) is a highly
conserved protein kinase implicated in the DNA damage response (DDR)
pathway that prevents the accumulation of DNA damage and controls reg-
ular genome duplication. CHK1 has been associated with prostate cancer
(PCa) induction, progression, and lethality; hence, CHK1 inhibitors
SCH900776 (also known as MK-8776) and the more effective SCH900776
analog MU380 may have clinical applications in the therapy of PCa. Syn-
ergistic induction of DNA damage with CHK1 inhibition represents a
promising therapeutic approach that has been tested in many types of
malignancies, but not in chemoresistant mCRPC. Here, we report that such
therapeutic approach may be exploited using the synergistic action of the
antimetabolite gemcitabine (GEM) and CHK1 inhibitors SCH900776 and
MU380 in docetaxel-resistant (DR) mCRPC. Given the results, both
CHK1 inhibitors significantly potentiated the sensitivity to GEM in a panel
of chemo-naı̈ve and matched DR PCa cell lines under 2D conditions.
MU380 exhibited a stronger synergistic effect with GEM than clinical
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candidate SCH900776. MU380 alone or in combination with GEM signifi-
cantly reduced spheroid size and increased apoptosis in all patient-derived
xenograft 3D cultures, with a higher impact in DR models. Combined
treatment induced premature mitosis from G1 phase resulting in the mito-
tic catastrophe as a prestage of apoptosis. Finally, treatment by MU380
alone, or in combination with GEM, significantly inhibited tumor growth
of both PC339-DOC and PC346C-DOC xenograft models in mice. Taken
together, our data suggest that metabolically robust and selective CHK1
inhibitor MU380 can bypass docetaxel resistance and improve the effective-
ness of GEM in DR mCRPC models. This approach might allow for dose
reduction of GEM and thereby minimize undesired toxicity and may repre-
sent a therapeutic option for patients with incurable DR mCRPC.
1. Introduction
Prostate cancer (PCa) represents one of the most
heterogeneous and clinically common malignancies in
men. Despite a high initial effectivity of androgen
deprivation therapy in localized disease with medium
and high risk, nearly half of the patients experience
progression to the incurable and lethal form termed
metastatic castration-resistant PCa (mCRPC) [1].
Treatment options for this advanced stage of the dis-
ease are rather limited. Specifically, docetaxel has been
used as the most effective treatment strategy for
mCRPC patients since 2004. Nevertheless, it gives only
modest survival benefit with most patients invariably
progressing due to acquired or inherent drug resistance
[2,3]. Due to the very low efficacy of chemotherapeu-
tics, prolonged anamnesis and resistance, the follow-up
therapies may pose more risk than help, indicating that
identification of new druggable targets in mCRPC is
crucial for the development of more efficient therapies.
DNA damaging therapy triggers various cellular
processes including DNA damage response (DDR),
cell cycle arrest, DNA repair, or apoptosis [4]. The
clinical genomics study of advanced PCa has demon-
strated that alterations in DDR genes such as loss of
BRCA1/2 or p53 function are present in almost one-
fourth of all mCRPC cases [5–7]. Checkpoint kinase 1
(CHK1) is a highly conserved protein kinase that is
activated at replication fork by single-stranded DNA
or bulky DNA lesions [8] to prevent cell cycle progres-
sion and recruit the DNA repair machinery to dam-
aged sites via CHK1-dependent Rad51
phosphorylation [9–12]. CHK1 acts as a distal trans-
ducer in the core DDR signaling network ataxia-te-
langiectasia and Rad3-related (ATR)-CHK1 which
along with ataxia-telangiectasia mutated (ATM)-
CHK2-p53 govern genomic stability and prevent
malignant transformations [13–15]. In cancer, the prin-
cipal activator of the ATR-CHK1 pathway is replica-
tion stress that is a consequence of activated
oncogenes and dysfunctional G1/S checkpoint control
[16]. Interestingly, androgen receptor (AR) signaling
has been reported to specifically regulate DDR genes
and its activity strongly correlates with the enhanced
activation of ATR-CHK1 axis, castration resistance,
metastasis, and decreased survival of PCa patients
[17,18]. Given the high-rate mutation events in DDR
in mCRPC, CHK1 remains an essential molecule for
controlling DDR and cell cycle and its targeting repre-
sents a particularly intriguing strategy for anticancer
therapy [19,20].
In our previous study, we reported the discovery of
the novel potent and selective CHK1 inhibitor MU380
[19]. This small molecule possesses a highly unusual N-
trifluoromethylpyrazole motif that renders the mole-
cule more metabolically robust to oxidative N-dealky-
lation, which is reflected in the compound’s favorable
in vivo properties.
A combination of MU380 and gemcitabine (GEM)
induces higher accumulation of DNA damage follow-
ing increased cell death in a variety of cancer cell lines
and is more effective in an in vivo mouse xenograft
model [19] than GEM plus the clinical candidate
SCH900776 [21]. Our recent study also demonstrated
that MU380 can sensitize lymphoid cancer cells to cyto-
toxic chemotherapeutic drugs such as GEM and flu-
darabine and that MU380 is effective as a single agent
in models with defective TP53 function [21]. Here, we
report a comprehensive investigation of the single-agent
efficacy of MU380 and its ability to potentiate the
effect of GEM in various resistant PCa models.
MU380 effectively sensitized all naı̈ve and docetaxel-re-
sistant (DR) cell lines by selective inhibition of GEM-
induced CHK1 autophosphorylation of Ser296. While
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MU380 monotherapy showed significant efficacy in
DR mCRPC PCa patient-derived xenografts (PDX),
importantly, combined treatment with GEM resulted in
significant tumor regression in the PC339-DOC and
PC346C-DOC xenografts, with observed efficacy of
MU380 monotherapy in PC339-DOC. Altogether, the
data provide an attractive preclinical rationale for fur-
ther clinical investigation of CHK1 inhibitors in the
context of eradication of aggressive, incurable mCRPC.
2. Material and methods
2.1. Cell lines, xenografts, and chemicals
Docetaxel-resistant DU145 and PC3 PCa cell lines
(indicated by no. 1) were derived as previously reported
[22]. Docetaxel resistance was maintained by a continu-
ous supply of docetaxel (Cell Signaling, Danvers, MA,
USA) in the final concentration of 12.5 nM. DR
DU145 and PC3 from Dublin (indicated by no. 2) were
generated as described previously [23]. Docetaxel resis-
tance was retained by the addition of 12 nM docetaxel
monthly. All cell lines were maintained at 37 °C (5%
CO2) in RPMI 1640 (Thermofisher Scientific, Waltham,
MA, USA) media supplemented with 10% FBS and
100 UmL−1 penicillin/streptomycin. The chemother-
apy-naı̈ve PC346C and PC339 xenografts and their DR
derivatives PC346C-DOC or PC339-DOC, respectively,
were established as described previously [24,25]. GEM
was purchased from Carbosynth Ltd (Compton, UK).
All cell models were routinely tested for mycoplasma
contamination. Cells were authenticated using
AmpFLSTR Identifiler Plus PCR Amplification Kit
(Thermofisher Scientific) to verify their origin. CHK1
inhibitors SCH900776 (currently in the second phase of
clinical trials) and novel MU380 (preclinical studies)
were synthesized as previously published [19].
2.2. Drug treatments
Cells were seeded and allowed to attach overnight.
Attached cells were treated with different concentra-
tions of GEM for 24 h, followed by the addition of
CHK1 inhibitors (either SCH900776 or MU380) for
2 h. Thereafter, the cells were replenished with fresh
medium and harvested for appropriate assay at the
indicated time points.
2.3. Cell proliferation assay
Cell proliferation was assessed by CyQUANT™ Cell
Proliferation Assay (Thermofisher Scientific). Wide-
spectra drug screening was performed on 384-well
plates (Corning, NY, USA). The cells were seeded in
the density of 20 000 cellscm−2 and cultivated for
24 h. Next, the treatment by the range of concentra-
tions of all drugs was performed with EpMotion®
5075 Automated Liquid Handling System (Eppendorf,
Hamburg, Germany), and cells were cultivated for the
next 48 h. CyQUANT™ Cell Proliferation Assay was
performed in the endpoint to analyze cell proliferation.
For the combined treatment analysis, the cells were
seeded in the density of 20 000 cellscm−2 into 96-well
plates (Corning). Twenty-four hours later, the cells
were treated with GEM (in MQ water) concentration
range for 24 h. The next day, the CHK1 inhibitors
SCH900776 (4 µM in DMSO) or MU380 (4 µM in
DMSO) were added for 2 h, followed by complete
media exchange. CyQuant assay was performed 48 h
post-treatments as recommended by the manufacturer.
The fluorescence was detected at 520 nm on a plate
reader Fluostar Galaxy (BMG Labtech, Ortenberg,
Germany).
2.4. 3D spheroid assay
Ten thousand cells per well were seeded into ultra-low
attachment 384-well plates (Corning) in the volume of
50 µL of media, the plates were centrifuged (10 min,
200 g) and cells allowed to proliferate and form spher-
oids in 48 h. After that time, the spheroids were pre-
treated with GEM (0.25 or 0.5 µM in fresh media) for
24 h followed by SCH900776 (4 µM in fresh media) or
MU380 (4 µM in fresh media) treatment. Forty-eight
hours later, cell viability was determined by CellTiter-
Glo luminescent cell viability assay (Promega, Madi-
son, WI, USA) according to the manufacturer’s rec-
ommendations. Luminescence was monitored at
560 nm using plate reader Infinite 200 PRO (Tecan,
Männedorf, Switzerland). Calcein AM and propidium
iodide (PI) were applied for the fluorescent analysis of
viable and dead cells using ImageXpress Micro XLS
Widefield High-Content Analysis System (Molecular
Devices, San Jose, CA, USA). The spheroid size was
determined by the quantification of transmitted light,
and fluorescent signal was quantified using high-con-
tent image analysis software METAXPRESS (Molecular
Devices).
2.5. Immunostaining
For immunofluorescence, cells were washed, fixed in
4% paraformaldehyde, permeabilized in 0.25% Triton
X-100, and blocked in 3% BSA containing 0.1% Tri-
ton X-100. Afterward, the cells were stained in
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suspension with biotin-conjugated primary antiphos-
pho-histone H3 followed by streptavidin-phycoerythrin
(PE) secondary antibody, anti-α-tubulin followed by
mouse Alexa Fluor 647-conjugated secondary antibody
and 40,6-diamidin-2-phenylindol (DAPI) for nuclear
localization. Cells were then washed twice, mounted
in Mowiol 4-88 (MilliporeSigma, Burlington, MA,
USA) + 0.6% 1,4-diazabicyclo[2.2.2]octane (Sigma-
Aldrich, St. Louis, MO, USA) as an antifade agent
and let dry for 2 h at 37 °C. Slides were analyzed by
Olympus FV10i scanning microscope using a 60×
objective. Material, clones, dilutions, catalog numbers,
and producers are listed in Table S3.
2.6. Immunoblotting
Cells were washed in PBS and harvested in radioim-
munoprecipitation assay buffer (Table S3) enriched with
protease inhibitors (Serva, Heidelberg, Germany) and
phosphatase inhibitor cocktail (MilliporeSigma). The
protein concentration was determined using a DC (deter-
gent-compatible) protein assay (Bio-Rad, Hercules, CA,
USA). The cell lysates were diluted to the same concen-
trations and mixed with loading buffer (150 mmolL−1
Tris–HCl pH 6.8, 3% SDS, 0.03% bromophenol blue,
30% glycerol, 3% β-mercaptoethanol). Equivalent pro-
tein quantities were separated by SDS/PAGE and trans-
ferred onto polyvinylidene difluoride membranes
(MilliporeSigma). The membranes were blocked in Tris-
buffered saline (TBS) containing 0.1% Tween-20 and 5%
nonfat dry milk for 1 h. The membranes were washed
with TBS–Tween and incubated with specific primary
antibodies overnight at 4 °C. The following primary anti-
bodies were used: CHK1, pCHK1 (S296), pCHK1
(S345), phosphorylated γH2A.X (pH2AX; S139), and β-
actin. The membranes were washed and then incubated
with secondary anti-mouse IgG or anti-rabbit IgG (GE
Healthcare, Chicago, IL, USA) antibodies for 1 h. Detec-
tion of antibody reactivity was performed using chemilu-
minescence substrate Immobilon Western HRP
Substrate (MilliporeSigma) and ChemiDoc™ Imaging
System (Bio-Rad). Dilutions, catalog numbers, and pro-
ducers are listed in Table S3.
2.7. Flow cytometry
The cells were seeded, 24 h later pretreated with GEM
and harvested at different time points 4, 12, and 24 h
after the treatment by MU380. The single-cell suspen-
sions were washed with PBS, fixed in 4% paraformalde-
hyde, permeabilized in 0.25% Triton X-100, and stained
under nonsterile conditions. For the analysis of the cell
cycle, FxCycle Violet Stain diluted in PBS was used.
The primary antiphospho-histone H2A.X antibody was
used to detect DNA damage. Biotin-conjugated primary
antiphospho-histone H3 together with streptavidin
PerCP-eFluor710-conjugated secondary antibodies were
used to detect mitotic cells. Dead cells were determined
by amine-reactive LIVE/DEAD Green Cell Viability
Assay (Thermofisher Scientific). For the apoptotic
assay, ApoFlowEx® FITC Kit (Exbio, Prague, Czech
Republic) was used according to the manufacturer’s
protocol. For RAD51 analysis, Alexa Fluor 488-conju-
gated primary antibody was used. Dead cells were
excluded by amine-reactive LIVE/DEAD Violet Cell
Viability Assay (Thermofisher Scientific). Mitochondrial
membrane potential was analyzed using the tetramethyl-
rhodamine, ethyl ester (TMRE) probe. The cells were
washed with Hanks’ balanced salt solution buffer and
stained for 20 min in diluted TMRE solution, final con-
centration 0.1 μM. Cells were analyzed by BD FACS-
Verse (Becton Dickinson, USA, three lasers—405, 488,
and 640 nm; eight detectors). Compensation values for
multicolor analyses were calculated automatically in BD
FACSSUITE Software (Becton Dickinson, Franklin Lakes,
NJ, USA) or FLOWJO (v10.0.7, Ashland, OR, USA)
from single-conjugate-stained UltraComp eBeads
(Thermofisher Scientific) or cell lines. Cell aggregates
and debris were excluded from the analysis based on a
dual-parameter dot plot in which the pulse ratio (signal
height/y-axis vs signal area/x-axis) was displayed. Mate-
rial, clones, dilutions, catalog numbers, and producers
are listed in Table S3.
2.8. Image stream analysis
Based on the protocol described above, the cells har-
vested 12 h after MU380 treatment were stained with
primary conjugated antiphospho-histone H2A.X and
anti RAD51 antibodies, biotin-conjugated primary
antiphospho-histone H3 with streptavidin-PE-Cy7-con-
jugated secondary and unconjugated primary M30
CytoDEATH, together with anti-mouse Alexa Fluor
647-conjugated secondary antibody. Co-staining with
DAPI probe was used for the quantification of DNA
content. Flow imaging was done using Amnis Image-
Stream Imaging Flow Cytometer (Luminex Corpora-
tion, Austin, TX, USA), with a given configuration
[one charge-coupled device (CCD) camera and six
detection channels]. Material, clones, dilutions, catalog
numbers, and producers are listed in Table S3.
2.9. Xenograft mouse experiments
Immunodeficient male mice severe combined immun-
odeficient (SCID) hairless outbred (SHO) (Crl:SHO-
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PrkdcscidHrhr) were from Charles River Laboratories
(Wilmington, MA, USA). A total of 1 × 106 of DR
PDXs PC346C-DOC and PC339-DOC were resus-
pended in the 1 : 1 mix of ice-cold PBS and Matrigel
(Corning) and inoculated subcutaneously into the right
flank (dorsally) of six-week-old male SHO mice. A
week after, when tumors became palpable, nine mice
per group were randomly divided into four cohorts
and treated by intraperitoneal administration of either
vehicle (Kolliphor ELP, Sigma-Aldrich), GEM
[150 milligram per kilogram body weight (mpk) dis-
solved in Kolliphor ELP, i.p. administration],
SCH900776 or MU380 (25 mpk dissolved in Kolliphor
ELP, i.p. administration), or combined approach as
also described previously [19]. The treatment was per-
formed in three cycles weekly (Fig. 5A). Tumor size
was measured twice a week by caliper. Tumor volume
was calculated using formula volume (mm3) =
(length × height2)/2. Mice were euthanized with CO2
4 weeks after inoculation and the tumors were
surgically excised, measured, weighed ex vivo and
frozen. All European Union Animal Welfare lines
(EU Directive 2010/63/EU for animal experiments)
were respected. Animal experiments were approved by
the Academy of Sciences of the Czech Republic
(AVCR 65/2016), supervised by the local ethical com-
mittee and performed by certified individuals (SD and
KS).
2.10. Statistical analysis
Data from the dose–response analysis were standardized as
% of control. A nonlinear regression to generate curves
with four-parameter dose–response model: Y¼Bottomþ
ðTopBottomÞ=ð1þ10ðLogIC50XÞHillSlopeÞ was used to
calculate half-maximal inhibitory concentration (IC50)
as the concentration of agonist that gave a response
that was halfway between Bottom and Top. HillSlope
coefficient denoted the steepness of the sigmoidal curve;
the top and bottom determined plateaus in the units of
the y-axis. The lower and upper bound of a 95% confi-
dence interval for IC50 was calculated. Heat map gener-
ation and cluster analyses were performed with
Morpheus (Broad Institute, Cambridge, MA, USA).
All statistical comparisons were analyzed with an
unpaired t-test, one-way ANOVA with Bonferroni cor-
rection or extra sum-of-squares F-test with Bonferroni
correction for IC50 comparison, where various letters
denote significant differences. Groups (GEM/GEM +
SCH900776/GEM + MU380) with the same letter are
not detectably different while groups that are detecta-
bly different have different letters. Groups can have
more than one letter to reflect overlaps. If the groups
have the same letter, this does not mean they are the
same, just not significantly different on the appropriate
level of significance.
3. Results
3.1. CHK1 inhibition by MU380 effectively
sensitizes docetaxel-resistant PCa cells to
gemcitabine
In our previous work [19], we identified MU380 as a
metabolically more robust nontrivial analog of the
CHK1 inhibitor SCH900776 (Fig. 1A,B). To identify
the potency of MU380 to sensitize DR PCa to
chemotherapy, we employed two sets of DR DU145
and PC3 cells along with their sensitive counterparts
(Table S1). Considering the data from drug screen-
ings addressing the sensitivity of all models to vari-
ous chemotherapy agents with different mechanisms
of action and molecular mechanism of CHK1 activa-
tion triggered by apical kinases ATM and ATR after
the induction of DNA damage [26], we selected
GEM as a suitable chemotherapy drug for the com-
bined treatment (Figs S1–S3). Next, we treated all
DR as well as control cell lines with different con-
centrations of GEM for 24 h to activate DDR, fol-
lowed by CHK1 inhibition by MU380 or
SCH900776 for 2 h (Fig. 1C). We compared the
effect of GEM monotherapy or combination with
CHK1 inhibitors on proliferation and determined
corresponding IC50 values. As shown, the combined
treatment with GEM and MU380 or SCH900776
was more effective than GEM monotherapy in a
majority of DR and control models, while the
monotherapy by MU380 or SCH900776 had no
impact on cell viability (Fig. 1D,E, Fig. S4 and Table
S2). Moreover, MU380 showed significantly higher
activity (reflected in the Loewe synergy score) in the
sensitization of DR DU145 and PC3 cells to GEM
compared to SCH900776 (Fig. 1F,G). Both CHK1
inhibitors elicited increased phosphorylation of DNA
damage sensor γH2A.X on S139 (pH2AX) after
GEM treatment. Again, a stronger effect was
observed for combination with MU380. As expected,
MU380 also effectively abrogated activation of
CHK1 via S296 autophosphorylation while simultane-
ously promoting DNA damage signaling toward
phosphorylation on S345 triggered by ATR (Fig. 1H,
I). Taken together, these results indicate that CHK1
inhibition, especially by MU380, efficiently sensitizes
DR cells to GEM leading to increased DNA damage
and reduced cell viability.
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3.2. S-phase delay is a consequence of combined
therapy-induced cytotoxicity
Next, we aimed to elucidate the effect of CHK1 inhibi-
tion on cell cycle distribution and apoptosis. The cell
cycle profile along with pH2AX and phosphorylated
mitotic marker Histone H3 phosphorylated on S10
(pHH3) was investigated using quantitative flow cytome-
try. For this purpose, we used the PC3 DR model and
previously determined IC50 of GEM (30 nM). We found
that GEM alone increased the population of cells in S-
phase and delayed progression into G2-phase (Fig. 2A,
B). Interestingly, CHK1 inhibition by MU380 prolonged
S/G2 progression and resulted in even higher accumula-
tion of cells in S-phase compared to GEM pretreated
cells only (Fig. 2A,B). A synergistic combination of
GEM and MU380 resulted in a significant increase of
DNA damage, determined by pH2AX compared to vehi-
cle and both monotherapy-treated samples at all time
points (Fig. 2C,D). Nevertheless, the combination of
both drugs did not substantially alter either the popula-
tion of mitotic cell death, apoptosis, or dead cells at the
endpoint of 24 h (Fig. 2E,F and Fig. S5A–F), in con-
trast to the significantly reduced cell viability at 48 h as
shown before. Usage of sublethal concentration of GEM
corresponding to IC75 increased both early apoptosis
and late apoptosis/secondary necrosis (Fig. 2E,F), indi-
cating that higher GEM concentration was able to
induce a stronger DDR response. This was further exac-
erbated by the significant increase of apoptosis in
DU145 DR cells (Fig. S5G,H). Together, these data sug-
gest that S-phase delay is the consequence of the cyto-
toxicity induced by combined treatment of GEM and
MU380, while forced mitotic cell death is not the cause
of cell death in the DR PC3 DR model.
3.3. MU380 induces cell death in docetaxel-
resistant PCa patient-derived xenografts in vitro
To further examine the effect of MU380, we employed
two previously established clinically relevant DR PDX
models [25]. DR PDXs were established in vivo by
serial passaging of androgen-responsive PC346C and
androgen-independent PC339 in male athymic mice
under docetaxel pressure until resistance [25]. Both
models bear a wild-type sequence of TP53 and can be
cultivated as floating 3D structures in vitro (Fig. 3A
and Table S1). Here, we investigated the effect of
GEM alone as well as in combination with
SCH900776 or MU380 on cell viability in vitro in 3D
spheroid cultures using the 3D spheroid assay. Dose–-
response analysis performed on floating spheroid cul-
tures of PDXs revealed limited response to GEM
alone (maximum cell death rate ~43% and ~34% in
PC346C-DOC and PC339-DOC, respectively) in both
models (Fig. 3B). Further, we selected two concentra-
tions of GEM (0.25 and 0.5 µM) and combined its
effect with 4 µM MU380 or SCH900776, in 3D single
spheroid conditions. Both doses of GEM elicited simi-
lar cell response and resulted in 20% or 40% viability
reduction for PC346C-DOC or PC339-DOC, respec-
tively. The combinations with MU380 contributed to a
significantly reduced cell viability in both DR as well
as naı̈ve models (Fig. 3C and Fig. S6). Compared to
SCH900776, the MU380 monotherapy was more cyto-
toxic in both models (Fig. 3C). As expected, GEM
(0.5 µM) alone did not strongly affect spheroid size and
viability. However, the combination with MU380
resulted in a significant reduction of both spheroid size
and viability (Fig. 3D,E and Fig. S6A–D). We also
observed a significant regression of spheroid size in
MU380 monotherapy-treated spheroids (Fig. 3D,E).
On the molecular level, CHK1 inhibition by MU380
disables autophosphorylation of CHK1 on S296 while
signals DNA damage by phosphorylation of pH2AX
and promotes DNA damage signaling via ATR-depen-
dent CHK1 phosphorylation on S345 (Fig. 3F).
Besides, treatment by MU380 led to significantly
decreased mitochondrial membrane potential (Fig. S7)
and an increased number of apoptotic cells, deter-
mined by Annexin V/PI assay (Fig. 3G,H). Altogether,
these results revealed unique activity and significance
Fig. 1. CHK1 inhibition by MU380 effectively sensitizes docetaxel-resistant PCa cells to GEM. (A) Structure of CHK1 inhibitors SCH900776
and MU380 and (B) activity of CHK1 and other kinases involved in cell cycle regulation after in vitro SCH900776 or MU380 (1 µM) inhibition.
(C) Timeline depicting treatment strategy. (D, F) Dose–response curves of relative viability of docetaxel-resistant DU145 (D) and PC3 (F)
cells, treated by a range of concentrations of GEM (in x-axis) alone or in combination with CHK1 inhibitors (SCH900776 or MU380) and
assessed by CyQUANT. The y-axis indicates the percentage of viable cells relative to control (MQ water or DMSO). Data represent
means  SEM (n ≥ 6) from three independent biological repetitions. **P < 0.0001; *P < 0.01 by extra sum-of-squares F-test. (E, G)
Synergy score of GEM and CHK1 inhibitors on docetaxel-resistant DU145 (E) and PC3 (G) cells analyzed using Loewe mathematical model
[high synergy (dark blue), low synergy (green), antagonism (dark red)]. Data represent means  SEM (n ≥ 6) from three independent
biological repetitions. *P < 0.01 by Loewe mathematical model. (H, I) Western blot analysis of pH2AX, pCHK1 (S296 and S345), total CHK1
and ß-actin as a loading control of the PC3 DR cells treated with GEM in combination with SCH900776 (H) or MU380 (I). Cells were
harvested 4, 12, and 24 h after the CHK1 inhibition treatment. ns., not significant, RFU, relative fluorescence unit.
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of MU380 as monotherapy and in combination with
GEM in clinically relevant docetaxel naı̈ve and resis-
tant PCa models.
3.4. MU380-driven premature mitosis is the
major cause of patient-derived xenograft cell
death
To elucidate the mechanism of how CHK1 inhibition
leads to the reduction of cell viability, we analyzed the
level of DNA damage simultaneously with DNA con-
tent, mitotic marker, and viability using multicolor
flow cytometry. Pretreatment of PC339-DOC cells by
0.25 μM GEM for 24 h induced G1-arrest associated
with a strong increase of DNA damage compared to
untreated cells (Fig. 4A). Noticeably, these cells were
not able to repair DNA and to proceed through the
cell cycle as they started to die from G1-phase in a
time-dependent manner (Fig. S8A). Conversely, the
addition of 4 μM MU380 to GEM pretreated cells led
to G1-checkpoint abrogation and progression to S-
phase at 24 h (Fig. 4A,B), further confirming the effect
of CHK1 inhibition. It also led to a massive increase
of pH2AX- and pHH3-double-positive cells from G1-
phase within 12 h (Fig. 4C and Fig. S8B–F), indicating
that these cells entered premature mitosis despite
GEM-induced DNA damage (Fig. 4C and Fig. S8B).
Subsequently, this resulted in a robust increase in cell
death after an extra 12- and 24-hr period compared to
the cells treated with GEM alone (Fig. S8G,H). More-
over, a single treatment of 4 μM MU380 induced S-
phase arrest within 12 h with increased DNA damage
and the number of dead cells in comparison with
untreated cells. Since the activation of DNA repair
mechanisms is CHK1 dependent, the levels of RAD51
(a signaling protein downstream of CHK1 that assists
with the repair of damaged DNA via homologous
recombination) were analyzed using flow cytometry.
We observed a significant elevation of the RAD51 sig-
nal after treatment with GEM, which was accompa-
nied by a sharp decrease to the basal level upon the
treatment with MU380 (Fig. S9A–C). Interestingly, a
strong increase in the subpopulation of RAD51 high
cells was observed upon the application of the
combined therapy. This subpopulation of cells was
also positive for pHH3 as well as pH2AX but not for
the marker of apoptosis M30, which is a product of
cytokeratin 18 cleavage (Fig. 4D–L). Therefore, we
investigated whether the potential mechanism of cell
death might be associated with mitotic catastrophe.
We observed that combined treatment resulted in an
enhanced number of pHH3-positive mitotic cells with
multinuclearization and disrupted cell division (Fig. 4
M and Fig. S9D) as hallmarks of mitotic catastrophe.
In summary, CHK1 inhibition by MU380 results in
the bypass of the GEM-induced G1-arrest leading to
premature mitosis, which is the main cause of cell
death in this DR PCa model.
3.5. MU380 effectively inhibits tumor growth in
docetaxel-resistant xenograft models
Finally, the antitumor effectivity of MU380 alone or
in combination with GEM was investigated in vivo
using PC346C-DOC or PC339-DOC PDXs. Immunod-
eficient male SHO mice were subcutaneously injected
with PC346C-DOC or PC339-DOC cells and left one
week to develop xenograft tumors. Tumor-bearing
mice were treated with three cycles of GEM (150 mpk)
followed by a bolus of MU380 (25 mpk) after 24 h
(combined therapy), or with one bolus of GEM or
MU380 or vehicle at 1, 2, and 3 weeks after inocula-
tion. Tumor size was measured twice a week (Fig. 5A).
We observed a significant reduction of tumor weight
and strong tumor growth inhibition in both PC339-
DOC and PC346C-DOC models (87% and 90%,
respectively) in the combined therapy group, which
was significantly more pronounced than either
monotherapy alone (Fig. 5B–E and Fig. S10A–C).
Notably, MU380 was effective also as monotherapy in
the reduction of tumor size and weight of PC339-DOC
and PC346C-DOC xenograft models (Fig. 5B–E,
Fig. S10A–C). The treatments did not significantly
affect mice body weights (Fig. S10D). Collectively,
these data suggest that inhibition of CHK1 by MU380
significantly potentiates the in vivo efficacy of GEM
and thus represents a promising approach for the ther-
apy of advanced DR PCa.
Fig. 2. S-phase delay as a consequence of combined therapy-induced cytotoxicity. (A) Cell cycle analysis of PC3 DR cells using FxCycle
Violet Stain. (B) Quantification of cell cycle kinetics from panel A. Data represent means  SEM from three independent biological
repetitions. (C) Analysis of pH2AX and cell cycle. (D) Quantification of DNA damage from panel C. Dead cells were excluded from the
analysis based on their positivity to LIVE/DEAD stain. Data represent means  SEM from three independent biological repetitions.
*P < 0.05, **P < 0.01; ***P < 0.001 by unpaired t-test. (E) Annexin V/PI-based analysis of apoptotic cells (endpoint 24 h). (F) Quantification
of Annexin/PI-positive cells from (E). The PC3 DR cells were harvested 4, 12, and 24 h after the MU380 treatment. Data represent
means  SEM from three independent biological repetitions. *P < 0.05, **P < 0.01 compared to the vehicle by unpaired t-test. #P < 0.05
compared to the GEM (100 nM) by unpaired t-test.
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Fig. 3. MU380 induces cell death in DR PCa PDXs in vitro. (A) Morphology of PC346C-DOC and PC339-DOC spheroids culture. Scale bar
100 μm. (B) GEM dose–response curves of relative viability of PC346C-DOC and PC339-DOC. Data represent means  SEM (n ≥ 6) from
three independent biological repetitions. (C) 3D spheroid assay, relative viability of PC346C-DOC and PC339-DOC spheroids treated by GEM
alone (0.25 and 0.5 µM) or in combination with CHK1 inhibitors (4 µM SCH900776 or MU380). Control spheroids were treated with vehicle.
The y-axis refers to a percentage of viable cells relative to vehicle (MQ water or DMSO). Data represent means  SEM (n ≥ 10) from two
independent biological repetitions. *P < 0.05 treatment vs control; #P < 0.05 GEM + SCH900776 or GEM + MU380 vs GEM alone;
▽P < 0.05 MU380 vs SCH900776 (alone or in combination) by unpaired t-test. (D, E) Representative images and quantification of spheroid
size and viability determined by calcein AM/PI of PC339-DOC spheroids treated with GEM (0.5 µM) or MU380 (4 µM) alone or their
combination in the endpoint of the 3D spheroid assay. Scale bar 100 μm. Data represent means  SEM (n ≥ 10) from two independent
biological repetitions. ***P < 0.001; by unpaired t-test. (F) Western blot analysis of pH2AX, pCHK1 (S296 and S345), total CHK1, and ß-actin
as a loading control on PC339-DOC spheroid cell culture. (G, H) Annexin/PI-based analysis of apoptotic cells and their quantification (H) on
PC339-DOC spheroid cell culture treated with GEM (0.5 µM) or MU380 (4 µM) alone or their combination. Data represent means  SEM
from three independent biological repetitions. *P < 0.05, ***P < 0.001 compared to the vehicle by unpaired t-test. #P < 0.05 compared to
the GEM (100 nM) by unpaired t-test. RLU, relative luminescence unit.
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Fig. 4. MU380-driven premature mitosis is the major cause of PDX cell death. (A) Flow cytometry analysis of cell cycle (FxCycle Violet),
DNA damage (pH2AX), and mitotic cells (pHH3) at the time point 12 h upon indicated treatment of the PC339-DOC model. (B)
Quantification of cell cycle depicted as kinetics in three time points for all treatments. Data represent means  SEM from three
independent biological repetitions. (C) Quantification of double-positive (pH2AX and pHH3) cells. The cells were harvested 4, 12 and 24 h
after the MU380 treatment. Dead cells were excluded from the analysis based on their positivity to LIVE/DEAD stain. Data represent
means  SEM from three independent biological repetitions. **P < 0.01; ***P < 0.001 by unpaired t-test. Multiparametric imaging flow
cytometry analysis of DNA content (DAPI), DNA repair (RAD51), DNA damage (pH2AX), apoptosis (M30), and mitosis (pHH3) 12 h after
MU380 treatment. Cell cycle distribution vs cells in mitosis in vehicle- (D) or GEM + MU30-treated (H) cells. RAD51 positivity in the pHH3
negative (F) or positive (G) subpopulations in the vehicle-treated and pHH3 negative (J), pHH3 positive from G2-phase (K), or pHH3 positive
from G1 and S-phase (L) in the GEM + MU380-treated PC339-DOC cells. Representative images of vehicle-treated (E) or GEM + MU380-
treated (I) cells from pregated subpopulations (D, H). (M) Microscopic analysis of DAPI, a-tubulin, and pHH3. The cells were harvested 12 h
after the MU380 treatment. Scale bar 10 µm.
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4. Discussion
Despite a better understanding of molecular mecha-
nisms and advances in the therapy of PCa, treatment
options for lethal, advanced mCRPC are still rather
limited. Small molecules represent an attractive and
promising group of agents that specifically target pro-
tein kinases employed in different signaling pathways.
Among these, DDR pathways have been considered as
suitable therapeutic targets alone, or in combination
with chemotherapy (Fig. S11A). Specifically, many
studies have been focusing on targeting CHK1 (mostly
in GEM pretreated cells) as a promising approach to
eradicate different types of cancer [27–31] because of
its unique and crucial role in the maintenance of geno-
mic integrity [32]. However, the effectivity and the
exact mechanism of this treatment strategy have not
been investigated in aggressive, chemoresistant sub-
types of mCRPC. Herein, we comprehensively investi-
gate the ability of the novel CHK1 inhibitor MU380
[19], a nontrivial analog of SCH900776 [33], to poten-
tiate the efficacy of GEM in DR PCa models (Fig.
S11A).
One of the most frequently asked questions in stud-
ies concerning inhibition of protein kinases employed
in DDR or cell cycle regulation, particularly CHK1, is
whether the p53 function or dysfunction affects thera-
peutic efficacy. A recent study of patient samples from
metastatic soft-tissue sarcomas identified TP53 muta-
tion as a crucial determinant of CHK1 inhibition
effectivity alone or in combination with GEM [34].
Nevertheless, in our previous study, we observed no
difference in the sensitization of the TP53-wt vs TP53-





Fig. 5. MU380 effectivity in DR PC346C and PC339 in vivo xenograft models. (A) Scheme depicting the in vivo experiment. (B, D) Plots
representing PC346C-DOC (B) or PC339-DOC (D) xenograft tumor volume in the mice treated with GEM or MU380 alone or their
combination on days 7, 14, and 21. Data represent tumor volume means  SEM (n = 9). *P < 0.05, **P < 0.01, ***P < 0.001 by repeated-
measures ANOVA. (C, E) Representative image of tumor size from differently treated groups of PC346C-DOC (C) or PC339-DOC (E) tumor-
bearing mice. Data represent tumor volume means  SEM (n = 9). s.c., subcutaneously; i.p. intraperitoneally.
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Similarly, CHK1 inhibition was found to augment the
effect of nucleoside analog fludarabine in incurable
chronic lymphocytic leukemia irrespective of TP53 sta-
tus [21,35]. This is consistent with our current data
demonstrating that both CHK1 inhibitors, SCH900776
and particularly MU380, effectively sensitized DR
TP53-null PC3 and TP53+/− DU145 cell lines as well
as DR TP53-wt PC346C and PC339 in vitro spheroid
cultures to GEM in a time-dependent manner. Irre-
spective of the significantly higher efficacy of MU380
compared to the clinical candidate SCH900776, the
effects of both inhibitors were associated with specific
inhibition of CHK1 autophosphorylation on S296 and
induction of DDR via ATR-dependent phosphoryla-
tion of CHK1 on S345. Furthermore, the level of the
DNA damage marker pH2AX was highest in cases of
combined treatments, suggesting replication stress as a
consequence of GEM sensitization.
Given the role of CHK1 in the regulation of intra
S- and G2/M-checkpoints [36], most studies attributed
CHK1 inhibition-induced sensitization of GEM-trea-
ted cells to cell cycle arrest abrogation associated with
premature mitotic entry [37]. Nevertheless, the
response of cells to combined therapy seems to be
more complex and depends on the degree of induced
genotoxicity. In previous studies, lower concentrations
of GEM resulted in prolongation of DNA synthesis
with modest S-phase arrest [38], ultimately enabling
mitotic entry. Koh et al. demonstrated that CHK1
inhibition of GEM pretreated cells results in a pro-
longed delay in the progression through S-phase
accompanied with enhanced DNA damage [29] (Fig.
S11B). In contrast, higher doses of GEM induced an
irreversible proliferation block and synchronization of
cells in G1-phase arrest [39], which resulted in forced,
premature mitosis upon CHK1 inhibition [29,40] (Fig.
S11C). This is consistent with our data, wherein the
PC3 DR cell line, a synergistic combination (in terms
of cytotoxicity) of GEM (30 nM) with MU380 engages
cells in disordered prolonged replication and then com-
mits them to elimination processes beyond mitosis. On
the other hand, a high dose of GEM (0.5 µM) in the
PC339-DOC model induced uniform and permanent
arrest in the G1 phase with time-dependent G1-phase
mitotic entry upon the MU380 treatment, resulting in
mitotic catastrophe and cell death. This suggests that
forced mitosis is not a unique mechanism responsible
for the sensitization of GEM by CHK1 inhibition.
Other mechanisms including disruption of HR via
RAD51 inhibition [41] or destabilization of DNA
replication [29] are likely to be involved, depending on
the extent of DNA damage induced by GEM dose.
Upon CHK1 inhibition, the cytotoxic effects are
attributed predominantly to increased rates of DNA
replication [19,29]. Considering CHK1 as a guard of
normal S-phase progression [42], loss of the CHK1-de-
pendent DNA damage checkpoint might result in a
replicative catastrophe and unavoidable cell death [43],
suggestive for the potential use of CHK1 inhibition
also as monotherapy. Numerous studies reported
CHK1 inhibition as a promising monotherapy option
to eradicate different types of malignancies [44–46]
and bypass chemoresistance [47]. This approach is
investigated also in clinical trials [48,49]. In consistence
with the previous study [21], we observed a significant
decrease in the viability of the MU380-monotherapy-
treated PC346C-DOC and PC339-DOC spheroid cul-
tures in vitro. This fact might be attributed to the func-
tional status of the AR. The AR was shown to be
mechanistically linked to DDR, more precisely to the
TopBP1-ATR-CHK1 axis, acting as an upstream
molecule which upregulates the expression of specific
DDR and DNA repair genes associated with metasta-
sis, castration resistance, and reduced overall survival
of PCa patients [18,19,50,51]. Karanika et al. proposed
the synergy between CHK1 and AR/CDC6 inhibition
as an effective strategy to induce DNA damage and
apoptosis, leading to effective treatment of mCRPC
[17,19]. These findings correlate with our data from
both in vitro and in vivo experiments showing higher
effectivity of the MU380 monotherapy in all AR-inde-
pendent models compared to the AR-responsive
PC346C model. Thus, single-agent CHK1 inhibition
by MU380 may serve as an important and promising
therapeutic strategy for mCRPC patients.
Observations from an in vitro PCa model have
shown that GEM acts in an antiproliferative as well as
inhibitory colony formation manner [52]. In the clini-
cal view, GEM may not be appropriate as first-line
therapy in PCa due to hematotoxicity and discrepancy
between the PSA response and the disease control rate
[53]. To increase the probability of clinical success, an
agent that causes DNA damage, oxaliplatin, was
added to GEM in a clinical trial in patients with PCa
after failure of chemotherapy [54]. Based on the PSA
response rate of 55% and radiologic response rate of
82%, one could expect that advanced PCa treatment
may build upon combined therapy with GEM.
Increased sensitivity to GEM was supposed to be asso-
ciated with the upregulation of ABCB1, which in con-
trast played a pivotal role in the development of
docetaxel resistance [55]. Even though it is still not
clear whether docetaxel-resistant patients could benefit
from GEM therapy, a recent study has demonstrated
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that GEM may be beneficial to effectively induce
tumor regression in the DR CRPC model.
5. Conclusion
The results of our experimental study provide evidence
that targeting CHK1 by MU380 can be used to signifi-
cantly improve the effectiveness of the clinically used
drug GEM, which supports the previous statements
(Fig. S11). Consequently, this combination might
allow for using lower doses of GEM, thereby reducing
the risk of major side effects [53]. This strategy might
be potentially also applicable to chemotherapy-naı̈ve
patients to avoid high toxicity and side effects of
chemotherapy and prevent the development of doc-
etaxel resistance. Altogether, these data provide a pre-
clinical rationale for the use of the CHK1 inhibitor
MU380 in a clinical setting for the therapy of incur-
able mCRPC.
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